logo-loader
viewVolitionRx

VolitionRx chief hails importance of colorectal cancer screening test CE mark

The boss of cancer diagnostics group VolitionRx (NYSE:VNRX) reckons the awarding of a CE mark for its Nu.Q Colorectal Cancer Screening Triage test could be transformational for the firm.

Chief executive Cameron Reynolds tells Proactive: “This is a very big deal for us. It really shifts the company from an R&D company to a product company.”

“It’s an extremely rewarding time for us and something we’re very happy about”

Reynolds also gives investors a run-through of how the test works and how it will work alongside current cancer screening methods.

On top of that, the VolitionRx boss discusses the progress being made as a whole, including an update on the development facility in Belgium purchased last October.

Quick facts: VolitionRx

Price: 4.55 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $186.97 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds discusses with Proactive London's Andrew Scott the results from the latest proof of concept study on its Nu.Q cancer-test assay. He says the finding's have revealed an impressive ability to detect with accuracy non-Hodgkins lymphoma...

6 days, 15 hours ago

2 min read